Literature DB >> 15271686

Homocysteine clearance and methylation flux rates in health and end-stage renal disease: association with S-adenosylhomocysteine.

Frank Stam1, Coen van Guldener, Piet M ter Wee, Willem Kulik, Desirée E C Smith, Cornelis Jakobs, Coen D A Stehouwer, Kees de Meer.   

Abstract

Hyperhomocysteinemia is a risk factor for cardiovascular disease and occurs frequently in end-stage renal disease (ESRD), but its pathogenesis is poorly understood. We aimed to evaluate one-carbon flux rates of methionine and homocysteine (Hcy) in ESRD patients and healthy controls. Transmethylation (TM), remethylation (RM), and transsulfuration (TS), as well as Hcy clearance by TS (i.e., TS/plasma total Hcy concentration) and by RM (i.e., RM/plasma total Hcy concentration) were evaluated in relation to body composition, vitamins, and S-adenosylhomocysteine (AdoHcy) and S-adenosylmethionine (AdoMet) levels. After a fixed protein diet for 3 days, primed-continuous infusion of [(2)H(3)-methyl-1-(13)C]methionine was performed in the postabsorptive state in 12 hemodialysis patients and 16 healthy volunteers. Hcy clearance by TS (-80%, P < 0.001) and by RM (-77%, P < 0.001) in ESRD patients was decreased compared with healthy controls. The absolute flux rates of TM (-27%, P < 0.01) and RM (-28%, P = 0.02) were lower in the ESRD patients. After adjustment for age, TS was not significantly reduced. Whole blood AdoHcy was significantly elevated in ESRD and was a significant determinant of TM (standardized beta = -1.24, P = 0.01) and RM (standardized beta = -1.43, P = 0.03). In conclusion, patients with ESRD have impaired Hcy clearance by TS and RM. Elevated whole blood AdoHcy levels are associated with impaired RM and TM flux rates in these patients, and AdoHcy may be a key regulatory compound in one-carbon flux.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15271686     DOI: 10.1152/ajprenal.00376.2003

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  7 in total

Review 1.  Homocysteine in Renal Injury.

Authors:  Yanjun Long; Jing Nie
Journal:  Kidney Dis (Basel)       Date:  2016-04-27

2.  Serum Metabolomics Benefits Discrimination Kidney Disease Development in Type 2 Diabetes Patients.

Authors:  Xiaofeng Peng; Xiaoyi Wang; Xue Shao; Yucheng Wang; Shi Feng; Cuili Wang; Cunqi Ye; Jianghua Chen; Hong Jiang
Journal:  Front Med (Lausanne)       Date:  2022-05-09

3.  Effects of S-adenosylmethionine on liver methionine metabolism and steatosis with ethanol-induced liver injury in rats.

Authors:  Zuojiong Gong; Shaonan Yan; Ping Zhang; Yanqing Huang; Luwen Wang
Journal:  Hepatol Int       Date:  2008-07-25       Impact factor: 6.047

4.  Homocysteine and Hypertension in Diabetes: Does PPARgamma Have a Regulatory Role?

Authors:  Utpal Sen; Suresh C Tyagi
Journal:  PPAR Res       Date:  2010-06-29       Impact factor: 4.964

5.  A population model of folate-mediated one-carbon metabolism.

Authors:  Tanya M Duncan; Michael C Reed; H Frederik Nijhout
Journal:  Nutrients       Date:  2013-07-05       Impact factor: 5.717

6.  Functional variants of the 5-methyltetrahydrofolate-homocysteine methyltransferase gene significantly increase susceptibility to prostate cancer: Results from an ethnic Han Chinese population.

Authors:  Yuan-Yuan Qu; Shu-Xian Zhou; Xuan Zhang; Rui Zhao; Cheng-Yuan Gu; Kun Chang; Xiao-Qun Yang; Hua-Lei Gan; Bo Dai; Hai-Liang Zhang; Guo-Hai Shi; Yao Zhu; Ding-Wei Ye; Jian-Yuan Zhao
Journal:  Sci Rep       Date:  2016-11-03       Impact factor: 4.379

Review 7.  Hyperhomocysteinemia: Metabolic Role and Animal Studies with a Focus on Cognitive Performance and Decline-A Review.

Authors:  Hendrik Nieraad; Nina Pannwitz; Natasja de Bruin; Gerd Geisslinger; Uwe Till
Journal:  Biomolecules       Date:  2021-10-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.